Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Intellia Thera CS (NQ: NTLA ) 23.58 -0.05 (-0.21%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Intellia Thera CS < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > 3 Gene-Editing Stocks With the Potential to Mint Millionaires December 13, 2023 Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. Via InvestorPlace Exposures Product Safety Could Intellia Therapeutics Become the Next CRISPR Therapeutics? December 12, 2023 Intellia is approaching the finish line. Via The Motley Fool You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. December 04, 2023 The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. Via The Motley Fool 2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market November 28, 2023 These stocks may take off in a market favoring growth. Via The Motley Fool 10 Health Care Stocks With Whale Alerts In Today's Session November 17, 2023 Via Benzinga Analyst Ratings for Intellia Therapeutics November 10, 2023 Via Benzinga 2 Brilliant Growth Stocks to Buy and Hold Forever October 12, 2023 These two growth stocks could be genuine wealth escalators. Via The Motley Fool Down 45%, Is Intellia a Buy? October 10, 2023 Intellia's operating in the high-growth field of gene editing. Via The Motley Fool Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session November 20, 2023 Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... Via Benzinga Why Intellia Therapeutics Stock Is Surging Tuesday November 14, 2023 Intellia Therapeutics Inc (NYSE: NTLA) shares are trading higher Tuesday after the company announced it received European Union orphan d Via Benzinga Cathie Wood Continues On Roku Shares Selling Spree After Company's Q3 Revenue Jump — Ark Sells $21.1M Of Stock November 13, 2023 Via Benzinga 3 Biotech Stocks That Are Betting on the Future of Gene Editing November 09, 2023 These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. Via InvestorPlace Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners November 06, 2023 Roku vaulted 50% to become Ark Innovation's top holding. Via Investor's Business Daily 1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years November 02, 2023 Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator. Via The Motley Fool Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy? October 28, 2023 There's more to being a good investment than doing groundbreaking science. Via The Motley Fool 3 Stocks Cathie Wood Is Buying That Should Be on Your List Too October 23, 2023 The three companies are positioned to benefit from red-hot trends. Via The Motley Fool Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time October 21, 2023 Wood is going all in on gene editing. Via The Motley Fool Cathie Wood's Ark Offloads $6.3M In Tesla Shares Amid EV Maker's Q3 Earnings Disappointment October 18, 2023 Via Benzinga 3 Gene Editing Stocks to Generate Super-Charged Gains October 18, 2023 As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. Via InvestorPlace Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing October 18, 2023 The company can begin a pivotal study of its treatment for cardiomyopathy. Via Investor's Business Daily 2 Healthcare Stocks Near 52-Week Highs Still Worth Buying October 16, 2023 These two large-cap biopharma companies could have more room to run. Via The Motley Fool 2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years October 14, 2023 These two gene-editing stocks could be diamonds in the rough. Via The Motley Fool Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row October 11, 2023 Via Benzinga Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares October 10, 2023 Via Benzinga This Cathie Wood Stock Is Poised to Double, Says Wall Street October 10, 2023 Almost anything is possible in the volatile biotech industry. Via The Motley Fool Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy? October 03, 2023 Don't bet the farm on the analysts being right -- but they might be. Via The Motley Fool Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases October 03, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Are Gene Therapy Stocks The Market's Next Big Winners? September 25, 2023 Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals September 23, 2023 Rocket could launch its medicines sooner, but Intellia is aiming for larger markets. Via The Motley Fool 1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know September 19, 2023 Good medicines aren't always good business. Via The Motley Fool < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.